- Update on Sexual Dysfunction: What can you do for your patients?
Barbara S. Levy, MD (September 2010)
A new study reveals that women who have low sexual arousal may experience a clinically significant change in symptoms after taking a placebo.
Does this finding suggest that ObGyns should use placebo when managing women who have sexual dysfunction?
But it does suggest that even simple interventions can make a difference in the management of these women, the authors say.
Andrea Bradford, PhD, a psychologist at Baylor College of Medicine, and coauthor Cindy Meston, PhD, a psychologist at the University of Texas at Austin, analyzed the behaviors and symptoms of 50 women who were randomly assigned to receive placebo in a large clinical trial of a drug treatment for low sexual arousal. Neither the women nor the study physicians knew whether they were taking the real drug or placebo.
After 12 weeks of treatment, symptoms in about one in three of these women improved to a degree that most clinicians would consider a meaningful change. Most of that improvement seemed to happen during the first four weeks of the study. Results were published online in the September 2010 issue of the Journal of Sexual Medicine.
The most important predictor of symptom change was an increase in the frequency of satisfying sexual encounters during the treatment. Many women even reported that they received more stimulation during sexual activity while they participated in the trial, even though their partners were not given any special instructions.
“It’s important to note that, even though these women received placebo, they all had an opportunity to talk to a health provider about their difficulties and were asked to closely monitor their sexual behavior and feelings over a 12-week period. Just taking part in this study probably started some meaningful conversations,” said Bradford. “Our study shows that even a limited intervention can have a positive effect in many women with sexual dysfunction. This comes as no surprise to sex therapists, but it does suggest a need to investigate behavioral factors more closely in clinical trials.”
We want to hear from you! Tell us what you think.